Potential pro‐tumour cytokine in oral squamous cellular carcinoma: IL37
Journal of Cellular and Molecular Medicine · 2024-11 · 28 (21)
DOI: 10.1111/jcmm.70167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 05.11.2024. Verfasst von Ying Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Stomatological Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Mouth Neoplasms, Carcinoma, Squamous Cell, Interleukin-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Health Commission & Science and Technology Bureau Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Inflammation and immunosuppression are important features of tumours, including oral squamous cellular carcinoma (OSCC). Interleukin 37 (IL37), a cytokine known for the ability to suppress inflammation and immunity, shows two seemingly contradictory functions in tumours. This study aims to investigate the mechanism that regulates IL37 and its role in OSCC progression. Herein, IL37, CD86 and CD206 in OSCC specimens were determined. Hypoxia, MCC950 and siRNA‐Gasdermin D (GSDMD) were utilised to investigate the mechanism of IL37 production and release. Animal experiments were established to examine the role of IL37 in OSCC growth in vivo. We found the levels of IL37 are elevated in OSCC tissues compared with normal oral mucosa. In cell experiments, hypoxia was proved to be a vital facilitator in IL37 expression and release. Mechanically, hypoxia promoted IL37 expression through the activation of NACHT–LRR–PYD‐containing protein 3 (NLRP3) inflammasome, and promoted IL37 release via GSDMD. Furthermore, IL37 levels in OSCC specimens are positively correlated with the number of M2 macrophages, but negatively with M1. Further studies revealed IL37 facilitated OSCC progression via promoting macrophage polarization from M1 to M2 and enhancing tumour cell proliferation. Thus, IL37 could be a promising target for OSCC treatment in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stomatological Hospital of Chongqing Medical University, Chongqing, China.
- Chongqing Key Laboratory for Oral Diseases and Biomedical Science, Chongqing, China.
- Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China.
ORCID-Profile: Jie Xu
Förderung
- Chongqing Health Commission & Science and Technology Bureau Foundation
- National Natural Science Foundation of China
Zitieren
APA
Yan, Y., Li, J., He, Y., Ji, P., Xu, J., & Li, Y. (2024). Potential pro‐tumour cytokine in oral squamous cellular carcinoma: IL37. Journal of Cellular and Molecular Medicine, 28(21). https://doi.org/10.1111/jcmm.70167
Vancouver
Yan Y, Li J, He Y, Ji P, Xu J, Li Y. Potential pro‐tumour cytokine in oral squamous cellular carcinoma: IL37. Journal of Cellular and Molecular Medicine. 2024;28(21). doi:10.1111/jcmm.70167
BibTeX
@article{Yan2024,
author = {Yan, Ying and Li, Jun and He, Yungang and Ji, Ping and Xu, Jie and Li, Yong},
title = {Potential pro‐tumour cytokine in oral squamous cellular carcinoma: IL37},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {21},
doi = {10.1111/jcmm.70167}
}
EUVIMED